Skip to content
Loading…
Attovia Therapeutics Inc., an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5 million in a US initial public offering.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.